Cargando…
P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL
Autores principales: | Maria Ribera, Josep, Morgades, Mireia, García-Calduch, Olga, Sirvent, Maialen, Buendía Ureña, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernández Rivas, Jesus, Sitges Arriaga, Marta, Garcia Cadenas, Irene, Abrisquet Acosta, Pablo, Montesinos, Pau, Bastos Oreiro, Mariana, Queipo de Llano, María-Paz, Bravo, Pilar, Torrent, Anna, Puente, Maria Pilar Herrera, Garcia-Guiñon, Antonio, Vall-Llovera Calmet, Ferran, Serrano, Josefina, Terol, Maria J, Burgues, Juan Miguel Bergua, García-Noblejas, Ana, Barrenetxea, Cristina, Llorente, Laura, García-Belmonte, Daniel, Gimeno, Eva, Cladera, Antonia, Mercadal Vilchez, Santiago, Manuel Sancho, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431106/ http://dx.doi.org/10.1097/01.HS9.0000971484.81356.4b |
Ejemplares similares
-
A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
por: Ribera, Josep‐Maria, et al.
Publicado: (2020) -
Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL
por: Marín-Sánchez, Alberto, et al.
Publicado: (2021) -
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
por: Barba, Pere, et al.
Publicado: (2022) -
Demographic, clinical and comorbidity data in a large sample of 1147 patients with migraine in Mexico City
por: Téllez–Zenteno, J. F., et al.
Publicado: (2005) -
S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)